Metastatic Breast Cancer Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
E
A Study of LY3023414 in Participants With Advanced Cancer - 2022
Completed
  • Advanced Cancer
  • +5 more
  • Los Angeles, California
  • +7 more
2022-04-07
Apr 7, 2022
W
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
Recruiting
  • Metastatic Breast Cancer
  • Leptomeningeal Disease
  • High-dose Methotrexate (8 gm/m2; HD-MTX)
  • Baltimore, Maryland
  • +2 more
2022-04-06
Apr 6, 2022
T
A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.
Recruiting
  • Advanced Breast Cancer
  • Metastatic Breast Cancer
  • Tianjin, Tianjin, China
    Breast Oncology, Tianjin Medical University Cancer Institute and
2022-04-06
Apr 6, 2022
E
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
Recruiting
  • Breast Cancer
  • +3 more
  • Gilbert, Arizona
  • +77 more
2022-04-06
Apr 6, 2022
N
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
Recruiting
  • Advanced Breast Cancer
  • +7 more
  • Anaheim, California
  • +4 more
2022-04-06
Apr 6, 2022
U
Dignity, Legacy, Advocacy, and Support for Advanced Cancer: Reimagined End of Life Care in the Black Community
Not yet recruiting
  • Metastatic Breast Cancer
  • DOULA-AC 1
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
2022-03-28
Mar 28, 2022
A
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
Recruiting
  • Metastatic Breast Cancer
  • Trastuzumab deruxtecan
  • +6 more
  • Iowa City, Iowa
  • +57 more
2022-04-05
Apr 5, 2022
U
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Recruiting
  • Breast Cancer
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin School of Medicine and Public Health
2022-04-04
Apr 4, 2022
N
Roll-over Study to Allow Continued Access to Ribociclib
Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
2022-04-04
Apr 4, 2022
E
Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Available
  • Metastatic Breast Cancer
  • Liverpool, New South Wales, Australia
  • +229 more
2022-04-05
Apr 5, 2022
H
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
Recruiting
  • Metastatic Breast Cancer
  • Trastuzumab Emtansine
  • +2 more
  • Fountain Valley, California
  • +133 more
2022-04-04
Apr 4, 2022
S
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Denosumab (reduced dosing)
  • Denosumab (standard dosing)
  • Feldkirch, Austria
  • +49 more
2022-04-04
Apr 4, 2022
V
Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer
Not yet recruiting
  • Metastatic Breast Cancer
  • Enobosarm & Abemaciclib Combo
  • non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant
  • Chandler, Arizona
  • +15 more
2022-04-01
Apr 1, 2022
V
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer
Recruiting
  • Metastatic Breast Cancer
  • Anchorage, Alaska
  • +50 more
2022-04-01
Apr 1, 2022
V
Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer
Not yet recruiting
  • Metastatic Breast Cancer
  • Sabizabulin
  • Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator
  • Anchorage, Alaska
  • +25 more
2022-04-01
Apr 1, 2022
S
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
Recruiting
  • Metastatic Breast Cancer
  • Ribociclib + Letrozole OR Fulvestrant
  • +2 more
  • Creixomil, Portugal
  • +44 more
2022-04-01
Apr 1, 2022
U
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
2022-03-31
Mar 31, 2022
A
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
Active, not recruiting
Has Results
  • Metastatic Breast Cancer
  • Veliparib Placebo
  • +3 more
  • Gilbert, Arizona
  • +218 more
2022-03-11
Mar 11, 2022
C
Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy
Not yet recruiting
  • Breast Neoplasms
  • +3 more
  • surgical treatment 1
  • +2 more
  • (no location specified)
2022-03-20
Mar 20, 2022
M
Nurse AMIE for Echo Show: Randomized Control Trial - 2022
Completed
  • Metastatic Breast Cancer
  • Nurse AMIE (Addressing Metastatic Individuals Every day)
  • Hershey, Pennsylvania
    Hershey Medical Center
2022-03-31
Mar 31, 2022
O
Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
Active, not recruiting
  • Metastatic Breast Cancer
  • Recurrent Breast Cancer
  • Boston, Massachusetts
  • +2 more
2022-03-21
Mar 21, 2022
A
Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer
Recruiting
  • Metastatic Breast Cancer
  • None (Observational study)
  • Macquarie, New South Wales, Australia
  • +42 more
2022-03-17
Mar 17, 2022
A
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
Recruiting
  • Invasive Breast Cancer
  • +3 more
  • Atlanta, Georgia
  • +5 more
2022-03-30
Mar 30, 2022
C
Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.
Not yet recruiting
  • Breast Cancer
  • Metastatic Breast Cancer
  • Blood sampling
  • Caen, France
    Centre François Baclesse
2022-03-21
Mar 21, 2022
U
Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer
Recruiting
  • Breast Cancer
  • +2 more
    • Monza, Italy
    • +2 more
    2022-03-29
    Mar 29, 2022